EuBiologics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Other Revenue	-0	-	-	0
Revenue	69,366	55,467	39,385	28,490
Revenue Growth (YoY)	25.06%	40.83%	38.24%	-
Cost of Revenue	35,405	31,918	24,167	21,590
Gross Profit	33,961	23,549	15,218	6,899
Selling, General & Admin	7,456	10,499	5,808	3,624
Research & Development	17,882	15,777	16,178	8,504
Other Operating Expenses	108.88	223.54	99.44	80.68
Operating Expenses	26,262	27,317	22,448	12,862
Operating Income	7,699	-3,769	-7,230	-5,962
Interest Expense	-488.05	-254.92	-588.81	-1,967
Interest & Investment Income	164.68	230.76	356.52	106.69
Earnings From Equity Investments	-512.58	-321.04	-124.61	-0.15
Currency Exchange Gain (Loss)	153.98	-56.99	40.34	-399.22
Other Non Operating Income (Expenses)	-1,191	-657.25	-22,818	-55,229
EBT Excluding Unusual Items	5,826	-4,828	-30,364	-63,451
Gain (Loss) on Sale of Investments	-200.32	2,142	253.29	-180.6
Gain (Loss) on Sale of Assets	1,666	193.28	-0.88	-5.24
Asset Writedown	-21,906	-845.09	-708.04	-
Other Unusual Items	-	-	-	3,041
Pretax Income	-14,615	-3,338	-30,820	-60,595
Income Tax Expense	745.04	99.24	-2,795	-460.79
Earnings From Continuing Operations	-15,360	-3,437	-28,025	-60,134
Minority Interest in Earnings	1,481	2,339	450.68	-
Net Income	-13,879	-1,099	-27,574	-60,134
Net Income to Common	-13,879	-1,099	-27,574	-60,134
Shares Outstanding (Basic)	36	36	35	28
Shares Outstanding (Diluted)	36	36	35	28
Shares Change (YoY)	0.13%	2.68%	26.53%	-
EPS (Basic)	-380.79	-30.19	-777.82	-2146.27
EPS (Diluted)	-381.00	-30.19	-778.00	-2146.27
Free Cash Flow	19,515	-2,626	-14,196	-6,371
Free Cash Flow Per Share	535.43	-72.15	-400.46	-227.38
Gross Margin	48.96%	42.45%	38.64%	24.22%
Operating Margin	11.10%	-6.79%	-18.36%	-20.93%
Profit Margin	-20.01%	-1.98%	-70.01%	-211.07%
Free Cash Flow Margin	28.13%	-4.74%	-36.05%	-22.36%
EBITDA	16,867	4,113	-665.51	-13.19
EBITDA Margin	24.32%	7.42%	-1.69%	-0.05%
D&A For EBITDA	9,168	7,882	6,564	5,949
EBIT	7,699	-3,769	-7,230	-5,962
EBIT Margin	11.10%	-6.79%	-18.36%	-20.93%
Advertising Expenses	186.94	237.98	47.13	35.88

Updated Mar 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.